Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study

Files in this item

This item appears in the following Collection(s)

Search DSpace



Browse

My Account

Statistics